Categories
  Encyclosphere.org ENCYCLOREADER
  supported by EncyclosphereKSF

Aron Mosnaim

From Wikipedia - Reading time: 7 min
Aron David Mosnaim
Occupation(s)Neuroscientist, researcher, and academic
Academic background
EducationPharmD degree
PhD in Organic Chemistry
Alma materUniversity of Chile
University of Strathclyde
Academic work
InstitutionsRosalind Franklin University of Medicine and Science
International Neuropsychiatry Consultants

Aron David Mosnaim is a neuroscientist, researcher, and academic. He is a professor of Cellular and Molecular Pharmacology and an adjunct professor of Psychiatry and Behavioral Sciences in the Chicago Medical School at Rosalind Franklin University of Medicine and Science.[1]

Mosnaim is most known for his research covering the areas of basic and clinical neuro- and immunopharmacology of biogenic amines and opioid peptides in neuropsychiatric conditions, including depression, headache pain, as well as movement and posttraumatic stress disorders.[2] He has co-edited four scientific books on Noncatecholic Phenylethylamines (2 volumes),[3] Posttraumatic Stress Disorder,[4] and Tardive Dyskinesia.[5]

Mosnaim has served as a Consultant to the Pan American Health Organization (1982–1985), Member of the United States Pharmacopeia Convention (1990 and 1995), and Director of International Neuropsychiatry Consultants (1987–2020). Additionally, he is a Fellow of The Chemical Society (1977) and a Senior Fellow of the American Institute of Therapeutics (2019).[1]

Early life and education[edit]

Mosnaim earned a Doctor of Pharmaceutical Sciences degree from the University of Chile (1964) and joined the Faculty of the university's School of Medicine. He was awarded a PhD degree in Organic Chemistry from Glasgow’s Strathclyde University (1969). After a brief tenure at the University of Chicago, he received a postdoctoral fellowship at Northwestern University (1970).[2]

Career[edit]

In 1971, Mosnaim joined the University of Health Sciences/The Chicago Medical School as an assistant professor in the Department of Pharmacology. He was promoted to Associate Professor and Acting Chairman (1974), and to a Full Professorship in 1979. He has been serving as a professor of Cellular and Molecular Pharmacology and adjunct professor of Psychiatry and Behavioral Sciences at The Chicago Medical School/Rosalind Franklin University.[1]

Mosnaim holds an Honorary Full Professorship at the University of Chile College of Pharmaceutical Sciences.

Research[edit]

Mosnaim has published over 150 papers in peer-reviewed Journals, more than 20 invited reviews and book chapters, and presented research in more than 200 scientific meetings.[2]

Early in his research career (1967), Mosnaim contributed to elucidate the metabolic pathway of the then widely used toxic insecticide DDT (dichlorodiphenyltrichloroethane), and in a series of publications (1969–1972) helped to understand the mechanism of halogenation by cupric salts of carcinogenic anthracene and pyrene compounds.[6] His laboratory demonstrated the presence of phenylethylamine, commonly viewed as the endogenous amphetamine, in mammalian tissues, and his work elucidated this amine’s in vivo and in vitro brain metabolic pathway.[7][8][9] His work, animal models, contributed to establish phenylethylamine brain levels as a biological marker for various neuropsychiatric disorders, and to evaluate its brain changes in response to different classes of psychotropic drugs.[10][11] Further research identified some of the physiological functions, and described relevant behavior and toxicological effects of phenylethylamine and various structurally related trace amines.[12][13]

Mosnaim reported plasma levels of the endogenous opioid pentapeptide methionine-enkephalin in various patient populations, and the effect of selected classes of drugs on its degradation kinetics,[14] suggesting that its significant increase in chronic cluster and migraine patients during an acute headache episode could serve as a biological marker for these illnesses.[15][16] He also clarified reports of the activity of platelet monoamine oxidase and the role of dietary phenylethylamine and tyramine in the etiology of migraine headaches.[17]

Mosnaim contributed to document the association of tardive dyskinesia and drug-induced parkinsonism, and in identifying sub-types, cognitive deficits, and some of the risk factors associated with increased vulnerability to this condition.[18][19][20][21] He participated in studies finding comorbidity of pain, dermatological and allergic conditions, as well as decreased natural killer cell activity, in posttraumatic stress disorder patients.[22] He reported the decrease of this immune function in septic shock and human immunodeficiency virus-1 positive individuals, as well as its significant increase by various substances with widely different chemical structures and biological activities, e.g., enkephalins, α-interferon, interleukin-2, taxol, and lipopolysaccharide.[23][24][25]

Bibliography[edit]

Selected edited books[edit]

  • Noncatecholic phenylethylamines Part 1 (1978) ISBN 0-8247-6616-4
  • Noncatecholic phenylethylamines Part 2 (1980) ISBN 0-8247-6721-7
  • Tardive Dyskinesia: Biological Mechanisms & Clinical Aspects (1989) ISBN O-8804-8176-5
  • Posttraumatic Stress Disorder: Etiology, Phenomenology, and Treatment (1990) ISBN 0-8804-8299-0

Selected articles[edit]

  • Inwang, E. E.; Mosnaim, A. D.; Sabelli, H. C. (May 1973). "Isolation and characterization of phenylethylamine and phenylethanolamine from human brain". Journal of Neurochemistry. 20 (5): 1469–1473. doi:10.1111/j.1471-4159.1973.tb00259.x. PMID 4716838. S2CID 8349615.
  • Sabelli, Hector C.; Mosnaim, A. David (June 1974). "Phenylethylamine Hypothesis of Affective Behavior". American Journal of Psychiatry. 131 (6): 695–699. doi:10.1176/ajp.131.6.695. PMID 4827802.
  • Wolf, Marion E; Alavi, Afshin; Mosnaim, Aron D (March 1988). "Posttraumatic stress disorder in vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine". Biological Psychiatry. 23 (6): 642–644. doi:10.1016/0006-3223(88)90011-x. PMID 3355879. S2CID 40512787.
  • Mosnaim, Aron D.; Ranade, Vasant V.; Wolf, Marion E.; Puente, Javier; Antonieta Valenzuela, M. (May 2006). "Phenothiazine Molecule Provides the Basic Chemical Structure for Various Classes of Pharmacotherapeutic Agents". American Journal of Therapeutics. 13 (3): 261–273. doi:10.1097/01.mjt.0000212897.20458.63. PMID 16772768.

References[edit]

  1. ^ a b c "Aron D. Mosnaim, PhD". Rosalind Franklin University.
  2. ^ a b c "Aron D Mosnaim". Walsh Medical Media.
  3. ^ Noncatecholic phenylethylamines. OCLC 3516955.[page needed][non-primary source needed]
  4. ^ Kinzie, J. David (October 1991). "Posttraumatic stress disorder: Etiology, phenomenology and treatment. By M. E. Wolf, and A. D. Mosnaim, editors. Washington, D.C.: American Psychiatric Press, Inc., 1990, 270 pages". Journal of Traumatic Stress. 4 (4): 607–608. doi:10.1002/jts.2490040416.
  5. ^ Wolf, Marion E.; Mosnaim, Aron D. (1988). Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. American Psychiatric Press. ISBN 978-0-88048-176-2. OCLC 17953812.[page needed][non-primary source needed]
  6. ^ Mosnaim, A.D.; Wolf, M.E.; Saavedra, I.; Amaro, A.M.; Cordano, G.; Nonhebel, D.C. (January 1973). "Reaction of cupric(ii) halides with organic compounds-VIII pyrene and some 3-substituted pyrenes". Tetrahedron Letters. 14 (17): 1491–1494. doi:10.1016/S0040-4039(01)95980-5.[non-primary source needed]
  7. ^ Mosnaim, AD; Inwang, EE; Sugerman, JH; DeMartini, WJ; Sabelli, HC (June 1973). "Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression". Biological Psychiatry. 6 (3): 235–57. PMID 4732254.[non-primary source needed]
  8. ^ Inwang, E. E.; Mosnaim, A. D.; Sabelli, H. C. (May 1973). "Isolation and characterization of phenylethylamine and phenylethanolamine from human brain". Journal of Neurochemistry. 20 (5): 1469–1473. doi:10.1111/j.1471-4159.1973.tb00259.x. PMID 4716838. S2CID 8349615.[non-primary source needed]
  9. ^ Mosnaim, Aron D.; Wolf, Marion E. (1978). Noncatecholic Phenylethylamines. M. Dekker. ISBN 978-0-8247-6616-0.[page needed][non-primary source needed]
  10. ^ Wolf, Marion E.; Mosnaim, A.D. (January 1983). "Phenylethylamine in neuropsychiatric disorders". General Pharmacology: The Vascular System. 14 (4): 385–390. doi:10.1016/0306-3623(83)90020-4. PMID 6352395.[non-primary source needed]
  11. ^ Sabelli, H. C.; Vazquez, A. J.; Mosnaim, A. D.; Madrid-Pedemonte, L. (March 1974). "2-Phenylethylamine as a possible mediator for Δ9-tetrahydrocannabinol-induced stimulation". Nature. 248 (5444): 144–145. Bibcode:1974Natur.248..144S. doi:10.1038/248144a0. PMID 4274244. S2CID 4168572.[non-primary source needed]
  12. ^ Mosnaim, Aron D.; Callaghan, Owen H.; Hudzik, Thomas; Wolf, Marion E. (April 2013). "Rat Brain-Uptake Index for Phenylethylamine and Various Monomethylated Derivatives". Neurochemical Research. 38 (4): 842–846. doi:10.1007/s11064-013-0988-1. PMID 23389662. S2CID 254860661.[non-primary source needed]
  13. ^ Mosnaim, Aron D.; Wolf, Marion E.; III. O’Donnell, James J.; Hudzik, Thomas (3 July 2020). "β-Phenylethylamine and various monomethylated and para-halogenated analogs. Acute toxicity studies in mice". Drug and Chemical Toxicology. 43 (4): 369–372. doi:10.1080/01480545.2018.1551899. PMID 30614291. S2CID 58557529.[non-primary source needed]
  14. ^ Mosnaim, Aron D.; Puente, Javier; Saavedra, Rolando; Diamond, Seymour; Wolf, Marion E. (2003). "In vitro Human Plasma Leucine5-Enkephalin Degradation Is Inhibited by a Select Number of Drugs with the Phenothiazine Molecule in Their Chemical Structure". Pharmacology. 67 (1): 6–13. doi:10.1159/000066781. PMID 12444298. S2CID 22740728.[non-primary source needed]
  15. ^ Mosnaim, Aron D.; Wolf, Marion E.; Chevesich, Jorge; Callaghan, Owen H.; Diamond, Seymour (July 1985). "Plasma Methionine Enkephalin Levels — A Biological Marker for Migraine?". Headache: The Journal of Head and Face Pain. 25 (5): 259–267. doi:10.1111/j.1526-4610.1985.hed2505259.x. PMID 4030316. S2CID 35728043.[non-primary source needed]
  16. ^ Mosnaim, Aron D.; Diamond, Seymour; Freitag, Frederick; Chevesich, Jorge; Wolf, Marion E.; Solomon, Glen (June 1987). "Plasma and Platelet Methionine-Enkephalin Levels in Chronic Cluster Patients During an Acute Headache Episode". Headache: The Journal of Head and Face Pain. 27 (6): 325–328. doi:10.1111/j.1526-4610.1987.hed2706325.x. PMID 3654188. S2CID 29924147.[non-primary source needed]
  17. ^ Mosnaim, A.D.; Freitag, F.; Karoum, F.; Wolf, M.E.; Diamond, S.; Salas, M.A. (April 1996). "Migraine and the contents of tyramine and phenylethylamine in food". Biological Psychiatry. 39 (7): 595. doi:10.1016/0006-3223(96)84270-3. S2CID 54244086.[non-primary source needed]
  18. ^ Wolf, ME; Chevesich, J; Lehrer, E; Mosnaim, AD (October 1983). "The clinical association of tardive dyskinesia and drug-induced parkinsonism". Biological Psychiatry. 18 (10): 1181–8. PMID 6140032.[non-primary source needed]
  19. ^ Wolf, Marion E.; Mosnaim, Aron D. (August 1984). "Identifying Subtypes of Tardive Dyskinesia". Psychiatric Services. 35 (8): 828–830. doi:10.1176/ps.35.8.828. PMID 6479919.[non-primary source needed]
  20. ^ Wolf, Marion E.; Ryan, Joseph J.; Mosnaim, Aron D. (August 1983). "Cognitive functions in tardive dyskinesia". Psychological Medicine. 13 (3): 671–674. doi:10.1017/S0033291700048108. PMID 6137851. S2CID 26957713.[non-primary source needed]
  21. ^ Wolf, ME; DeWolfe, AS; Ryan, JJ; Lips, O; Mosnaim, AD (September 1985). "Vulnerability to tardive dyskinesia". The Journal of Clinical Psychiatry. 46 (9): 367–8. PMID 2863257.[non-primary source needed]
  22. ^ Wolf, M. E; Alavi, A.; Mosnaim, A. D. (1988). "Pain, dermatological and allergic conditions in post traumatic stress disorder". Pain, Dermatological and Allergic Conditions in Post Traumatic Stress Disorder. 13 (3): 237–240. INIST 7009885.[non-primary source needed]
  23. ^ Maturana, Patricio; Puente, Javier; Miranda, Dante; Sepulveda, Cecilia; Wolf, Marion E.; Mosnaim, Aron D. (March 1991). "Natural killer cell activity in patients with septic shock". Journal of Critical Care. 6 (1): 42–45. doi:10.1016/0883-9441(91)90032-O.[non-primary source needed]
  24. ^ Sepúlveda, Cecilia; Puente, Javier; Weinstein, Caroline; Wolf, Marion E.; Mosnaim, Aron D. (November 1997). "Enhancement of natural killer cell activity in HIV-1-infected subjects by a mixture of the calcium ionophore A23187 and the phorbol ester TPA: lack of response to a similar challenge with interleukin-2 or α-interferon". American Journal of Therapeutics. 4 (11): 413–422. doi:10.1097/00045391-199711000-00013. PMID 10423640. S2CID 42963577.[non-primary source needed]
  25. ^ Puente, J; Carvajal, T; Parra, S; Miranda, D; Sepulveda, C; Wolf, ME; Mosnaim, AD (June 1993). "In vitro studies of natural killer cell activity in septic shock patients. Response to a challenge with alpha-interferon and interleukin-2". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 31 (6): 271–275. PMID 8335423.[non-primary source needed]
Licensed under CC BY-SA 3.0 | Source: https://en.wikipedia.org/wiki/Aron_Mosnaim
3 views | Status: cached on February 25 2024 16:39:45
↧ Download as ZWI file
Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF